Otsuka Pharmaceutical Acquires Transcend Therapeutics
March 27, 2026
Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.
- Buyers
- Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc., Otsuka America Pharmaceutical, Inc.
- Targets
- Transcend Therapeutics, Inc.
- Sellers
- Transcend shareholders
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Taconic Biosciences Acquires TransCure bioServices
January 20, 2026
Biotechnology
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
Otsuka Pharmaceutical Acquires Jnana Therapeutics
August 1, 2024
Biotechnology
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
Otsuka Pharmaceutical Acquires Mindset Pharma
August 31, 2023
Biotechnology
Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.
-
AbbVie Acquires Syndesi Therapeutics
March 1, 2022
Biotechnology
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
-
Sanofi Acquires Translate Bio in $3.2 Billion Deal
August 3, 2021
Biotechnology
Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.
-
Shionogi Acquires Tetra Therapeutics
May 26, 2020
Biotechnology
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.